ENSCHIGH SIGNALFINANCIAL10-K

ENSC shows extreme financial volatility with SG&A expenses exploding 1,520% while simultaneously reporting positive net income and executing massive share buybacks exceeding $136M.

The dramatic spike in SG&A expenses alongside massive share buybacks suggests either significant one-time events or accounting irregularities that require immediate investor scrutiny. The combination of deteriorating operations (operating losses widened 52%) with positive net income and enormous buyback activity creates an internally inconsistent financial picture that raises red flags about the company's true financial condition.

Comparing 2026-03-30 vs 2025-03-10View on EDGAR →
FINANCIAL ANALYSIS

ENSC's financials show extreme contradictions with SG&A expenses surging over 1,500% and R&D costs rising 44%, yet the company somehow achieved positive net income of $2.4M compared to $366K previously. Most dramatically, share buybacks exploded from $11.6M to $136.3M while operating losses deepened significantly. This combination of massive cost increases, widening operational losses, yet positive bottom-line results alongside unprecedented buyback activity suggests either major one-time items or potential accounting irregularities that investors must investigate immediately.

FINANCIAL STATEMENT CHANGES
SG&A Expense
P&L
+1520.2%
$1.2M$18.7M

SG&A up 1520.2% — significant increase in sales or administrative costs, monitor impact on operating leverage.

Share Buybacks
Cash Flow
+1076.5%
$11.6M$136.3M

Share repurchases increased 1076.5% — management returning capital, signals confidence in intrinsic value.

Net Income
P&L
+557.1%
$366K$2.4M

Net income grew 557.1% — bottom-line growth signals improving overall business health.

Interest Expense
P&L
+223.2%
$110K$354K

Interest expense surged 223.2% — significant debt increase or rising rates materially impacting earnings.

Current Liabilities
Balance Sheet
+106.9%
$2.2M$4.6M

Current liabilities surged 106.9% — significant near-term obligations; verify ability to meet short-term debt.

Total Liabilities
Balance Sheet
+106%
$2.2M$4.6M

Liabilities grew 106% — significant increase in debt or obligations, assess impact on financial flexibility.

Operating Income
P&L
-52.2%
-$6.7M-$10.2M

Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.

R&D Expense
P&L
+43.7%
$7.2M$10.4M

R&D investment increased 43.7% — signals commitment to future product development, though near-term margin impact.

Current Assets
Balance Sheet
+35.5%
$5.3M$7.2M

Current assets grew 35.5% — improving short-term liquidity or inventory/receivables build.

Total Assets
Balance Sheet
+33.1%
$5.6M$7.5M

Asset base grew 33.1% — expansion through organic growth, acquisitions, or capital deployment.

LANGUAGE CHANGES
NEW — 2026-03-30
PRIOR — 2025-03-10
ADDED
Nasdaq may delist our common stock and/or our Public Warrants may not continue to trade on the Pink Limited Market operated by OTC Markets Group, Inc..
2025 Registered Direct Offering A definitive Securities Purchase Agreement with certain institutional investors, pursuant to which the Company agreed to issue and sell in a registered direct offering shares of common stock and pre-funded warrants for an aggregate amount of $1.1 million.
2025 March Warrant Offering An agreement by the Company to issue and sell unregistered warrants of Common Stock, Series A-5, and Series A-6 warrants to purchase shares of Common Stock.
2025 April Warrant Inducement The Company s April 2025 Inducement offer letter entered into with certain holders of existing warrants to purchase 630,376 shares of the Company s common stock (issued in March of 2025) and the issuance of new warrants exercisable for an aggregate of up to 1,260,752 shares of common stock with an exercise price of $1.90 per share.
ANDA Abbreviated New Drug Application API Active pharmaceutical ingredient AUC Area under the concentration time curve August Inducement Letter Inducement offer letter entered into with certain holders of existing warrants to purchase 480,234 shares of the Company s common stock (issued in February of 2024) to reduce the exercise price from $15.90 per share to $7.05 per share.
+7 more — sign up free →
REMOVED
Nasdaq may delist our common stock and/or our Public Warrants may not continue to trade on the OTC Pink Open Market.
ADFs Abuse deterrent formulations ADHD Attention deficit hyperactivity disorder ANDA Abbreviated New Drug Application API Active pharmaceutical ingredient AUC Area under the concentration time curve August Inducement Letter Inducement offer letter entered into with certain holders of existing warrants to purchase 480,234 shares of the Company s common stock (issued in February of 2024) to reduce the exercise price from $15.90 per share to $7.05 per share.
is a clinical stage pharmaceutical company that is developing a compound utilized in the Company s overdose protection program for the treatment of COVID-19 and 79.2%-owned subsidiary of the Company EB-ST Agreement Agreement and Plan of Merger, dated as of December 28, 2015, by and among Signature, SAQ, and EB EMA European Medicines Agency Ensysce Ensysce Biosciences Inc.
GAAP Generally Accepted Accounting Principles in the United States of America GCP Good Clinical Practices GMP Good Manufacturing Practices Hatch-Waxman Act or Hatch-Waxman Amendments Drug Price Competition and Patent Term Restoration Act of 1984 HHS United States Department of Health and Human Services IMPDs Investigational Medicinal Product Dossiers IND Investigational New Drug Investor Notes The 2021 Notes, 2022 Notes and 2023 Notes, collectively.
Securities and Exchange Commission Securities Act Securities Act of 1933, as amended Securities Purchase Agreement The Securities Purchase Agreement, dated as of September 24, 2021, June 30, 2022, October 23, 2023, or August 28, 2024 as the context dictates, by and between Ensysce and the institutional investors party thereto Signature Signature Therapeutics Inc.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →